bell
The current prices are delayed by 15 mins, login to check live prices.
Alivus Life Sciences Ltd share price logo

Glenmark Life Sciences Share Price

(ALIVUS)

₹1104.71.88%

as on 04:01PM, 20 Jan 2025

Overview
News
Financials
Q3 2024 Results
Technicals

Glenmark Life Sciences Analyst Rating

based on 5 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 5 analysts offering long term price targets for Glenmark Life Sciences. An average target of ₹1138.6

Source: S&P Global Market Intelligence

Glenmark Life Sciences Share analysis

Glenmark Life Sciences price forecast by 5 analysts

Upside of5.00%

High

₹1295

Target

₹1138.60

Low

₹1015

Glenmark Life Sciences target price ₹1138.6, a slight upside of 5% compared to current price of ₹1104.7. According to 5 analysts rating.

Source: S&P Global Market Intelligence

Glenmark Life Sciences Performance

  • Day's Low

    Day's High

    ₹1,064.7
    Day's Price Range
    ₹1,125
  • 52 Week's Low

    52 Week's High

    ₹676.5
    52-Week Price Range
    ₹1,335.1
1 Month Return+ 7.01 %
3 Month Return-2.57 %
1 Year Return+ 35.8 %
Previous Close₹1,084.35
Open₹1,089.95
Volume82.51K
Upper Circuit-
Lower Circuit-
Market Cap₹13,286.85Cr

Glenmark Life Sciences Key Statistics

P/E Ratio0
PEG Ratio0
Market Cap₹13,286.85 Cr
P/B Ratio4.07
EPS0
Dividend Yield0
SectorPharmaceuticals
ROE21.07

Glenmark Life Sciences Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹13,286.85 Cr8.97%0.51NANA
NA₹887.14 Cr244.49%0.62₹28 Cr₹125 Cr
NA₹75.29 Cr11.76%0.78₹2 Cr₹45 Cr
NA₹14.25 Cr233.33%0.50NANA
NA₹13.61 Cr15.24%0.69NANA

About Glenmark Life Sciences

Glenmark Life Sciences Private Limited (formerly Zorg Laboratories Private Limited) was incorporated as a private limited company on 23 June 2011. It was acquired by Glenmark Pharmaceuticals Limited in July 2018, and was converted to a public company in August 2018. Operating as a wholly-owned subsidiary of Glenmark Pharmaceuticals, the company is engaged in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs). The company has Research and Development (R&D) facilities in Mahape, Ankleshwar, and Dahej, while its manufacturing facilities are located in Ankleshwar, Dahej, Mohol, and Kurkumbh. On 13 August 2018, Glenmark Life Sciences allotted 4,500,090 equity shares of Rs. 10 each upon conversion of a loan given to the Director, and 15,000,000 shares to its parent company Glenmark Pharmaceuticals under preferential allotment. The company recently concluded its IPO, of a total of 21,022,222 equity shares, raising Rs. 15136 million. All of the outstanding purchase consideration was repaid from the proceeds of the IPO, and the company’s equity shares are now listed on both the BSE and NSE.

Share Price: ₹1104.70 per share as on 20 Jan, 2025 04:01 PM
Market Capitalisation: ₹13,286.85Cr as of today
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
OrganisationGlenmark Life Sciences
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Alivus Life Sciences Ltd

  • Glenmark Life Sciences Rebrands as Alivus Life Sciences - 20 Jan, 2025

    Glenmark Life Sciences has officially changed its name to Alivus Life Sciences following its acquisition by Nirma. This rebranding reflects the company's renewed vision and commitment to growth in the API and CDMO sectors, symbolizing vitality and transformation.

Insights on Alivus Life Sciences Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 1.01% to 2.82% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.82% to 7.85% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 10.76% to 12.98% in Sep 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 46.6% return, outperforming this stock by 14.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 103.2% return, outperforming this stock by 39.5%

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 82.85% to 75.00% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, ALIVUS stock has moved down by -3.9%

Glenmark Life Sciences Financials

Value in ₹ crore
Details2021202220232024
Total Assets₹1,999.10Cr (-)₹2,472.09Cr (↑23.66%)₹2,703.98Cr (↑9.38%)₹2,854.97Cr (↑5.58%)
Total Liabilities₹1,246.35Cr (-)₹417.77Cr (↓66.48%)₹565.77Cr (↑35.43%)₹522.64Cr (↓7.62%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹195.01Cr (-)₹388.11Cr (↑99.02%)₹597.59Cr (↑53.97%)₹306.01Cr (↓48.79%)₹413.52Cr (↑35.13%)

Index Inclusions

BSE Small-Cap

₹52,739.01

0.82 (427.7%)

BSE Healthcare

₹42,986.13

0.76 (325.87%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Glenmark Life Sciences Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
75%
-9.48
Foreign Institutions
7.85%
63.12
Mutual Funds
2.82%
178.19
Retail Investors
12.98%
20.63
Others
1.34%
140.56

Glenmark Life Sciences Key Indicators

Details20202021202220232024
Return On Equity %127.8460.9129.8322.2821.07

Glenmark Life Sciences Earnings and Dividends

  • Alivus Life Sciences Ltd Earnings Results

    Alivus Life Sciences Ltd’s net profit fell -19.72% since last year same period to ₹95.32Cr in the Q2 2024-2025. On a quarterly growth basis, Alivus Life Sciences Ltd has generated -14.5% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Alivus Life Sciences Ltd Dividends October,2023

    In the quarter ending September 2023, Alivus Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 3.94%.

    Read More about Dividends

Glenmark Life Sciences Technicals Summary

Bearish

Neutral

Bullish

Bullish

Alivus Life Sciences Ltd is currently in a Bullish trading position according to technical analysis indicators.

FAQs on Alivus Life Sciences Ltd

Alivus Life Sciences Ltd share price today stands at ₹1104.7, Open. ₹1089.95 ; Previous Close. ₹1084.35 ; High. ₹1125 ; Low. ₹1064.7 ; 52 Week High. ₹1335.1 ; 52 Week Low: ₹676.5.

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Alivus Life Sciences Ltd shares.

Alivus Life Sciences Ltd is listed on NSE

Alivus Life Sciences Ltd is listed on BSE

  • Today’s highest price of Alivus Life Sciences Ltd is ₹1125.
  • Today’s lowest price of Alivus Life Sciences Ltd is ₹1064.7.

Today’s traded volume of Alivus Life Sciences Ltd(ALIVUS) is 82.51K.

Today’s market capitalisation of Alivus Life Sciences Ltd(ALIVUS) is ₹13286.85Cr.

Alivus Life Sciences Ltd(ALIVUSPrice
52 Week High
₹1335.1
52 Week Low
₹676.5

Alivus Life Sciences Ltd(ALIVUS) share price is ₹1104.7. It is down -17.26% from its 52 Week High price of ₹1335.1

Alivus Life Sciences Ltd(ALIVUS) share price is ₹1104.7. It is up 63.30% from its 52 Week Low price of ₹676.5

Alivus Life Sciences Ltd(ALIVUSReturns
1 Day Returns
20.35%
1 Month Returns
7.01%
3 Month Returns
-2.57%
1 Year Returns
35.8%